WEBULL
WebtradeDownload

U.S. Physical Therapy (USPH) Stock Looks Cheap Even After A 38% Run

Simply Wall St · 2d ago

U.S. Physical Therapy has enjoyed a strong share price run, and the real question now is whether the current valuation lines up with the cash flows that underpin the business. After a move like this, investors may want to know if the market is simply reacting to headlines or if the cash generation profile can reasonably support where the stock trades today.

  • The stock is up 38.2% over the past year, which puts real pressure on the idea that recent gains are matched by equally durable cash flows.
  • Fresh hospital partnerships and higher reimbursement rates can influence expectations for future operating cash, as they affect both visit volumes and pricing power.
  • If you'd rather focus on sales, this one's for you. See why U.S. Physical Therapy's 1.8x P/S tells a different valuation story.

The issue now is whether U.S. Physical Therapy's current share price is justified by the cash flows implied by a Discounted Cash Flow (DCF) view.

If you want to compare U.S. Physical Therapy's cash flow story with a wider set of businesses that also lean on fundamental strength, you can line it up beside results from solid balance sheet and fundamentals stocks screener (25 results)

Is U.S. Physical Therapy a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what U.S. Physical Therapy could be worth based on the cash it is expected to generate for shareholders. Over the last twelve months the group produced roughly $73.4 million of free cash flow, and the model assumes that this figure continues to grow rather than shrink over the coming decade. Those projections step down over time from analyst forecasts to gentler growth estimates, which fits a business that is expected to expand but not at a breakneck pace forever.

The DCF output suggests that these projected cash streams imply an intrinsic value substantially above the current share price of $99.49. Because the latest Q3 2026 earnings beat came on the back of higher visit volumes and better reimbursement rates, the market reaction so far still leaves the stock trading below what the model implies for U.S. Physical Therapy's cash generation potential. Find out what U.S. Physical Therapy could be worth using our Discounted Cash Flow (DCF) estimate.

The U.S. Physical Therapy Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this valuation puzzle for U.S. Physical Therapy leaves off by spelling out the specific growth, margin and earnings paths that would need to play out for the stock to be worth materially more or materially less than it is today on the market. Instead of stopping at a single output from a ratio or model, Narratives clarify the future that number relies on so you can watch in real time whether those conditions actually show up in U.S. Physical Therapy's results.

One of the top community narratives on U.S. Physical Therapy: roughly fairly valued

"The main thing that has to go right is that hospital affiliation growth, technology investments and the expanding Industrial Injury Prevention segment together offset rising employee medical costs…"

Discover why this Narrative puts U.S. Physical Therapy at roughly fairly valued.

Before acting on U.S. Physical Therapy's valuation, there is one more factor to weigh

Cash flows and share price only tell part of the story at U.S. Physical Therapy, because the people steering the clinics and how they are rewarded can pull outcomes in very different directions. See who runs U.S. Physical Therapy and how they are paid.